Lambert-Eaton myasthenic syndrome can undergo acute, crisis-like deterioration that requires prompt, targeted clinical action. This protocol addresses that specific situation and outlines the structured approach for managing sudden or severe worsening.
The focus is on patients with Lambert-Eaton myasthenic syndrome who experience crisis-like deterioration — an acute presentation distinct from stable disease management and requiring an escalated, evidence-based response.
The approach centres on immunotherapy-based interventions for acute crisis — the specific options, their selection criteria, and the full clinical algorithm are detailed in the complete protocol.
DOI: 10.1177/17562864231213240
IVIg or, if appropriate, PE/IA must be used to treat the crisis worsening.
IVIg should be recommended as helpful in the treatment of LEMS on this basis and on the basis of expert evidence, both as short-term and long-term therapy.
View source ↗